Bliss GVS Pharma Reaches 52-Week High of Rs. 181.35 with 42.53% Annual Return

Bliss GVS Pharma, a small-cap player in the pharmaceuticals and drugs industry, has recently reached a new 52-week high of Rs. 181.35 on January 1, 2025. The stock has shown strong performance, outperforming its sector by 7.79% today. Over the past six days, Bliss GVS Pharma has experienced consecutive gains, accumulating a total return of 11.29%.

The stock’s intraday high of Rs. 181.35 reflects a 10.14% increase for the day. Additionally, Bliss GVS Pharma is currently trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in its price movement.

In terms of annual performance, Bliss GVS Pharma has delivered a notable return of 42.53% over the past year, significantly outpacing the Sensex, which has recorded an 8.20% increase during the same period. The stock’s recent performance highlights its resilience and growth within the competitive pharmaceuticals sector.

Related Posts

Pvt nursing home sealed in Chatra after woman, unborn baby die

Chatra: The Chatra administration on Sunday sealed a private nursing home operating near Chatra bus stand following the death of a 20-year-old pregnant woman and her unborn child. The deceased…

30 docs from 9 states guilty of taking pharma company junket, no action yet by 6 state medical councils

Thirty doctors who were found guilty of accepting a foreign trip worth Rs 2 crore to Paris and Monaco, funded by a pharma company, come from at least nine states.…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Pvt nursing home sealed in Chatra after woman, unborn baby die

Pvt nursing home sealed in Chatra after woman, unborn baby die

30 docs from 9 states guilty of taking pharma company junket, no action yet by 6 state medical councils

30 docs from 9 states guilty of taking pharma company junket, no action yet by 6 state medical councils

Scheme to build bulk drugs’ R&D, capacity in works, says Pharma secy

Scheme to build bulk drugs’ R&D, capacity in works, says Pharma secy

Drug companies directed to step up vigil on adverse reactions

Drug companies directed to step up vigil on adverse reactions

Maharashtra FDA seizes medical devices, gloves worth ₹2.17 cr in crackdown on irregularities

Maharashtra FDA seizes medical devices, gloves worth ₹2.17 cr in crackdown on irregularities

AI-designed universal coronavirus vaccine passes first human trial

AI-designed universal coronavirus vaccine passes first human trial